{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:28:54Z","timestamp":1785796134600,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113872","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:36:50Z","timestamp":1734395810000},"page":"113872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2409-3497","authenticated-orcid":false,"given":"Lin","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113872_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.seizure.2023.09.008","article-title":"Febrile infection-related epilepsy syndrome in childhood: a clinical review and practical approach","volume":"111","author":"van Baalen","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.intimp.2024.113872_b0010","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ana.25439","article-title":"Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome","volume":"85","author":"Clarkson","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2024.113872_b0025","first-page":"5","article-title":"Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis","volume":"48","author":"van Baalen","year":"2017","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.intimp.2024.113872_b0030","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/epi.16275","article-title":"Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus","volume":"60","author":"Kothur","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0035","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17933","article-title":"Second-line immunotherapy in new onset refractory status epilepticus","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0040","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-024-07363-5","article-title":"Febrile infection-related epilepsy syndrome with claustrum lesion: an underdiagnosed inflammatory encephalopathy","author":"Bai","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.intimp.2024.113872_b0045","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1212\/WNL.0000000000013261","article-title":"Teaching neuroimage: claustrum sign in febrile infection-related epilepsy syndrome","volume":"98","author":"Muccioli","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2024.113872_b0050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.0000000000001996","article-title":"Claustrum damage and refractory status epilepticus following febrile illness","volume":"85","author":"Meletti","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2024.113872_b0055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/acn3.51348","article-title":"Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy","volume":"8","author":"Pensato","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2024.113872_b0060","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/epi.13801","article-title":"Early ictal and interictal patterns in FIRES: the sparks before the blaze","volume":"58","author":"Farias-Moeller","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0065","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/epi.17591","article-title":"Treatment of new onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult","volume":"64","author":"Girardin","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2024.113872_b0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1212\/WNL.0000000000207068","article-title":"Bridging the gap: tailoring an approach to treatment in febrile infection-related epilepsy syndrome","volume":"100","author":"Goh","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2024.113872_b0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.110.077214","article-title":"18F-FDG PET reveals frontotemporal dysfunction in children with fever-induced refractory epileptic encephalopathy","volume":"52","author":"Mazzuca","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.intimp.2024.113872_b0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/B978-0-444-53486-6.00051-X","article-title":"Neuroimaging of epilepsy","volume":"136","author":"Cendes","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113872_b0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/epi.13311","article-title":"PET hypermetabolism in medically resistant childhood epilepsy: incidence, associations, and surgical outcome","volume":"57","author":"Bansal","year":"2016","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.intimp.2024.113872_b0090","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2967\/jnumed.120.256081","article-title":"Hypermetabolism on pediatric PET scans of brain glucose metabolism: what does it signify","volume":"62","author":"Chugani","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:53:06Z","timestamp":1736614386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924023944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"alternative-id":["S1567576924023944"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113872","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113872"}}